pubmed-article:15673746 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:15673746 | lifeskim:mentions | umls-concept:C0019682 | lld:lifeskim |
pubmed-article:15673746 | lifeskim:mentions | umls-concept:C2349001 | lld:lifeskim |
pubmed-article:15673746 | lifeskim:mentions | umls-concept:C0681850 | lld:lifeskim |
pubmed-article:15673746 | lifeskim:mentions | umls-concept:C1706203 | lld:lifeskim |
pubmed-article:15673746 | lifeskim:mentions | umls-concept:C2697811 | lld:lifeskim |
pubmed-article:15673746 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
pubmed-article:15673746 | lifeskim:mentions | umls-concept:C0525005 | lld:lifeskim |
pubmed-article:15673746 | lifeskim:mentions | umls-concept:C1446409 | lld:lifeskim |
pubmed-article:15673746 | lifeskim:mentions | umls-concept:C0870883 | lld:lifeskim |
pubmed-article:15673746 | lifeskim:mentions | umls-concept:C1550501 | lld:lifeskim |
pubmed-article:15673746 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
pubmed-article:15673746 | pubmed:issue | 2 | lld:pubmed |
pubmed-article:15673746 | pubmed:dateCreated | 2005-1-27 | lld:pubmed |
pubmed-article:15673746 | pubmed:abstractText | In order to evaluate the potential risk of nelfinavir (NFV) accumulation in human immunodeficiency virus (HIV)-hepatitis C virus (HCV)-coinfected patients with liver disease, we investigated the concentrations of NFV and M8, the active metabolite of NFV, in plasma HIV-positive (HIV+) patients coinfected with HCV. A total of 119 HIV+ subjects were included in our study: 67 HIV+ patients, 32 HIV+ and HCV-positive (HCV+) patients without cirrhosis, and 20 HIV+ and HCV+ patients with cirrhosis. Most of the enrolled patients (chronically treated) were taking NFV at the standard dosage of 1,250 mg twice a day. To assay plasma NFV and M8 concentrations, patients underwent serial plasma samplings during the dosing interval at steady state. Plasma NFV and M8 concentrations were measured simultaneously by a high-performance liquid chromatography method with UV detection. The HIV+ and HCV+ patients with and without cirrhosis had significantly lower NFV oral clearances than the HIV+ and HCV-negative individuals (28 and 58% lower, respectively; P < 0.05), which translated into higher areas under the concentration-time curves for cirrhotic and noncirrhotic patients. The NFV absorption rate was significantly lower in cirrhotic patients, resulting in a longer time to the maximum concentration in serum. The mean ratios of the M8 concentration/NFV concentration were significantly lower (P < 0.05) in HIV+ and HCV+ subjects with cirrhosis (0.06 +/- 0.074) than in the subjects in the other two groups. The mean ratios for M8 and NFV were not statistically different between HIV+ and HCV-negative patients (0.16 +/- 0.13) and HIV+ and HCV+ patients without cirrhosis (0.24 +/- 0.17), but the interpatient variability was high. Our results indicate that the pharmacokinetics of NFV and M8 are altered in HIV+ and HCV+ patients, especially those with liver cirrhosis. Therefore, there may be a role for therapeutic drug monitoring in individualizing the NFV dosage in HIV-HCV-coinfected patients. | lld:pubmed |
pubmed-article:15673746 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15673746 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15673746 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15673746 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15673746 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15673746 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15673746 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15673746 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15673746 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15673746 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15673746 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15673746 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15673746 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15673746 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15673746 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15673746 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15673746 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15673746 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15673746 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15673746 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15673746 | pubmed:language | eng | lld:pubmed |
pubmed-article:15673746 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15673746 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:15673746 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15673746 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15673746 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:15673746 | pubmed:month | Feb | lld:pubmed |
pubmed-article:15673746 | pubmed:issn | 0066-4804 | lld:pubmed |
pubmed-article:15673746 | pubmed:author | pubmed-author:RegazziMarioM | lld:pubmed |
pubmed-article:15673746 | pubmed:author | pubmed-author:FabrisPaoloP | lld:pubmed |
pubmed-article:15673746 | pubmed:author | pubmed-author:MaseratiRenat... | lld:pubmed |
pubmed-article:15673746 | pubmed:author | pubmed-author:NardiniGiulia... | lld:pubmed |
pubmed-article:15673746 | pubmed:author | pubmed-author:GattiFrancesc... | lld:pubmed |
pubmed-article:15673746 | pubmed:author | pubmed-author:VillaniPaolaP | lld:pubmed |
pubmed-article:15673746 | pubmed:author | pubmed-author:CusatoMariaM | lld:pubmed |
pubmed-article:15673746 | pubmed:author | pubmed-author:ZucchiPatrizi... | lld:pubmed |
pubmed-article:15673746 | pubmed:author | pubmed-author:BrigantiElena... | lld:pubmed |
pubmed-article:15673746 | pubmed:author | pubmed-author:RodaRinaldoR | lld:pubmed |
pubmed-article:15673746 | pubmed:author | pubmed-author:SacchelliLuca... | lld:pubmed |
pubmed-article:15673746 | pubmed:author | pubmed-author:Delle... | lld:pubmed |
pubmed-article:15673746 | pubmed:author | pubmed-author:MoriFernandaF | lld:pubmed |
pubmed-article:15673746 | pubmed:author | pubmed-author:CastelliPaula... | lld:pubmed |
pubmed-article:15673746 | pubmed:author | pubmed-author:TestaLuciaL | lld:pubmed |
pubmed-article:15673746 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:15673746 | pubmed:volume | 49 | lld:pubmed |
pubmed-article:15673746 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:15673746 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:15673746 | pubmed:pagination | 643-9 | lld:pubmed |
pubmed-article:15673746 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
pubmed-article:15673746 | pubmed:meshHeading | pubmed-meshheading:15673746... | lld:pubmed |
pubmed-article:15673746 | pubmed:meshHeading | pubmed-meshheading:15673746... | lld:pubmed |
pubmed-article:15673746 | pubmed:meshHeading | pubmed-meshheading:15673746... | lld:pubmed |
pubmed-article:15673746 | pubmed:meshHeading | pubmed-meshheading:15673746... | lld:pubmed |
pubmed-article:15673746 | pubmed:meshHeading | pubmed-meshheading:15673746... | lld:pubmed |
pubmed-article:15673746 | pubmed:meshHeading | pubmed-meshheading:15673746... | lld:pubmed |
pubmed-article:15673746 | pubmed:meshHeading | pubmed-meshheading:15673746... | lld:pubmed |
pubmed-article:15673746 | pubmed:meshHeading | pubmed-meshheading:15673746... | lld:pubmed |
pubmed-article:15673746 | pubmed:meshHeading | pubmed-meshheading:15673746... | lld:pubmed |
pubmed-article:15673746 | pubmed:meshHeading | pubmed-meshheading:15673746... | lld:pubmed |
pubmed-article:15673746 | pubmed:meshHeading | pubmed-meshheading:15673746... | lld:pubmed |
pubmed-article:15673746 | pubmed:meshHeading | pubmed-meshheading:15673746... | lld:pubmed |
pubmed-article:15673746 | pubmed:meshHeading | pubmed-meshheading:15673746... | lld:pubmed |
pubmed-article:15673746 | pubmed:meshHeading | pubmed-meshheading:15673746... | lld:pubmed |
pubmed-article:15673746 | pubmed:meshHeading | pubmed-meshheading:15673746... | lld:pubmed |
pubmed-article:15673746 | pubmed:meshHeading | pubmed-meshheading:15673746... | lld:pubmed |
pubmed-article:15673746 | pubmed:meshHeading | pubmed-meshheading:15673746... | lld:pubmed |
pubmed-article:15673746 | pubmed:meshHeading | pubmed-meshheading:15673746... | lld:pubmed |
pubmed-article:15673746 | pubmed:meshHeading | pubmed-meshheading:15673746... | lld:pubmed |
pubmed-article:15673746 | pubmed:year | 2005 | lld:pubmed |
pubmed-article:15673746 | pubmed:articleTitle | Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects. | lld:pubmed |
pubmed-article:15673746 | pubmed:affiliation | Clinical Pharmacokinetic Unit, Department of Pharmacology, IRCCS Policlinico San Matteo, Piazzale Golgi 1, 27100 Pavia, Italy. regazzim@smatteo.pv.it | lld:pubmed |
pubmed-article:15673746 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:15673746 | pubmed:publicationType | Clinical Trial | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15673746 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15673746 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15673746 | lld:pubmed |